Franchi Jean M.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Biodesix Expands MRD Monitoring Through New Partnerships. Biodesix announced progress in two collaborative programs aimed at tumor‑informed and tumor‑naïve molecular residual disease (MRD) solutions. The company also advanced its MRD monitoring programs by partnering with Bio‑Rad and Thermo Fisher. These developments broaden Biodesix’s portfolio of diagnostic tools for cancer patients.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Replimune Launches TUDRIQEV Amidst Mixed Analyst Views. Replimune Group has launched TUDRIQEV, marking a key step in its commercial strategy. Analysts are currently assessing the product's potential, with some suggesting a wait-and-see approach until market performance becomes clearer. The stock is trading near significant support levels, reflecting cautious sentiment as investors evaluate the new launch.
Transaction History
| IRON | ▼ Sell | Open Market | 6,257 | $433K | 4/14/2026 | View on chart |
| IRON | ▼ Sell | Open Market | 400 | $28K | 4/13/2026 | View on chart |
| IRON | ▼ Sell | Open Market | 353 | $24K | 2/25/2026 | View on chart |
| IRON | ▼ Sell | Open Market | 3,397 | $221K | 2/18/2026 | View on chart |
| IRON | ▼ Sell | Open Market | 3,684 | $243K | 2/18/2026 | View on chart |
| IRON | ▼ Sell | Open Market | 4,075 | $256K | 2/17/2026 | View on chart |
| IRON | ▲ Buy | Grant | 19,000 | $0 | 2/10/2026 | View on chart |
| IRON | ▼ Sell | Open Market | 2,031 | $120K | 7/17/2025 | View on chart |
| IRON | ▼ Sell | Open Market | 2,000 | $115K | 7/10/2025 | View on chart |
| IRON | ▼ Sell | Open Market | 2,000 | $105K | 6/16/2025 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 26,368 | — | 4/1/2025 | View on chart |
| IRON | ▼ Sell | Open Market | 3,136 | $171K | 2/18/2025 | View on chart |
| IRON | ▲ Buy | Grant | 36,000 | $0 | 2/10/2025 | View on chart |
| IRON | ▲ Buy | Grant | 36,666 | $0 | 2/7/2024 | View on chart |
| BDSX | ▲ Buy | Grant | 61,728 | $100K | 8/3/2023 | View on chart |
| REPL | ▼ Sell | Open Market | 11,351 | $205K | 5/16/2023 | View on chart |
| REPL | ▲ Buy | Grant | 45,000 | $0 | 4/1/2023 | View on chart |
| REPL | ▼ Sell | Open Market | 3,436 | $50K | 5/16/2022 | View on chart |
| REPL | ▲ Buy | Grant | 52,500 | $0 | 4/1/2022 | View on chart |
| BDSX | ▲ Buy | Option Exercise | 20,044 | — | 3/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Disc Medicine faces valuation scrutiny and whale activity
Recent commentary questions whether Disc Medicine's stock price fully reflects its market position relative to competitors. Additionally, the stock appeared on a list of healthcare names showing significant large-scale trading activity. The stock is currently trading near its 52-week low, which provides context for these recent market observations.
Disc Medicine faces valuation scrutiny and whale activity. Recent commentary questions whether Disc Medicine's stock price fully reflects its market position relative to competitors. Additionally, the stock appeared on a list of healthcare names showing significant large-scale trading activity. The stock is currently trading near its 52-week low, which provides context for these recent market observations.